Sigilon Therapeutics Augments Intellectual Property Portfolio with Recent U.S. Patents

64

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sigilon Therapeutics today announced the addition to its patent portfolio of U.S. Patent Nos. 10,285,949 and 10,292,936.

 

Read More: http://www.businesswire.com/news/home/20190610005022/en/Sigilon-Therapeutics-Augments-Intellectual-Property-Portfolio-U.S.